A recent study demonstrated that combining BH3-mimetic drugs targeting BCL-2, BCL-XL, and MCL-1 still cannot reverse the resistance caused by CD40 stimulation in CLL cells [50]. The gene discussed is BCL2L1; the disease is B-cell chronic lymphocytic leukemia.